ArticleMMWR. Morbidity and mortality weekly report2025
Synthetic Opioid and Stimulant Co-Involved Overdose Deaths by Occupation and Industry - United States, 2022.
Article in MMWR. Morbidity and mortality weekly report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Daily patterns of opioid and stimulant use and associated risk-behavior outcomes: A cohort study.Addictive behaviors · 2026Article
- Opioid and Stimulant Coprescriptions among South Carolina Residents.Southern medical journal · 2026Article
- Transitions from first drug use to illicit opioid and injection drug use in a multisite rural U.S. cohort of people who use drugs.Harm reduction journal · 2026Article
- Crack/cocaine use to manage xylazine exposure in fentanyl in Connecticut: findings from a convergent mixed methods study.Harm reduction journal · 2026Article
- Syringe service program leader and participant perspectives on reasons for opioid-stimulant co-use in the United States.Drug and alcohol dependence reports · 2025Article
- Controlled Substance Prescribing Patterns Among Fatal Overdose Decedents with an Opioid, Stimulant, or Both Contributing to Death - Pennsylvania, 2017-2022.MMWR. Morbidity and mortality weekly report · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proportion of synthetic opioid overdose deaths co-involving stimulants has increased in the United States in recent years. Although persons who use opioids have reported increasing stimulant co-use to maintain workplace productivity and alertness, occupational patterns of co-involvement in fatal overdose have not been systematically investigated. In an exploratory study, data on overdose deaths involving synthetic opioids (e.g., fentanyl) from the 2022 National Vital Statistics System were analyzed to characterize patterns of stimulant co-involvement among U.S. residents aged 15-64 years, stratified by decedents' usual occupation and industry. Of 69,893 fatal synthetic opioid overdoses, 53.6% involved stimulants. Occupation and industry groups with the highest percentages of synthetic opioid overdose deaths co-involving psychostimulants with abuse potential (psychostimulants) were typically physically demanding (e.g., construction and extraction occupations), whereas categories with highest percentages of cocaine co-involvement were generally less physically strenuous (e.g., business and financial occupations); these patterns might reflect differences in desired drug effects, cost, and geographic availability. Work-related interventions might be useful in preventing the development of substance use disorder by decreasing rates of occupational injuries and workplace stress, connecting workers with substance use disorder to treatment resources, and reducing fatal overdose through harm reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.